CN105997974A - Application of rosmarinic acid to preparing medicines for treating asthma - Google Patents
Application of rosmarinic acid to preparing medicines for treating asthma Download PDFInfo
- Publication number
- CN105997974A CN105997974A CN201610570798.2A CN201610570798A CN105997974A CN 105997974 A CN105997974 A CN 105997974A CN 201610570798 A CN201610570798 A CN 201610570798A CN 105997974 A CN105997974 A CN 105997974A
- Authority
- CN
- China
- Prior art keywords
- rosmarinic acid
- group
- treating asthma
- asthma
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of rosmarinic acid to preparing medicines for treating asthma. The application has the advantages that mouse asthma models are built under the induction effects of ovalbumin, and accordingly effects of the rosmarinic acid for treating asthma can be proved; the rosmarinic acid is low in toxicity and few in toxic effects when used for treating asthma, excellent cure effects can be realized when the rosmarinic acid is used for treating asthma, and the like.
Description
Technical field
The present invention relates to pharmaceutical technology field, the application in preparation treatment asthmatic medicament of a kind of rosmarinic acid.
Background technology
Rosmarinic acid, English name: rosmarinci acid, is in labiate Herba Rosmarini Officinalis the one of isolated
Plant water miscible natural phenolic acid compounds.Chemical name is R (t) 2-[[3-(3,4. dihydroxy phenyl)-1-oxo-2-propylene
Base] epoxide]-3,4-dihydroxy benzenes propanoic acid, by a part caffeic acid and a part 3,4. DLA condensation forms.Fan
The most fragrant acid is widely distributed in plant, is distributed mainly on many plantations such as Labiatae, Boraginaceae, Umbelliferae, Cucurbitaceae and Duan Shu section
In thing, rosmarinic acid is dietotherapeutic herbaceous plant, is available for viewing and admiring and extracting fragrance, is alternatively arranged as food seasoning.Numerous studies
Show that rosmarinic acid has many-sided pharmacological action such as antioxidation, antibacterial, antiviral, antidepressant.At present, rosmarinic acid is in system
The fields such as medicine, food, cosmetics have embodied its important using value.But there are no rosmarinic acid for treating asthma
Relevant report.
Asthma is a serious health problems all existed all over the world, badly influences daily life, has
Time even fatal harm.Allergic asthma is the conducting airways obstacle of a kind of heterogeneity, including chronic airway inflammation, air flue
Function reduction and air flue tissue remodeling.Its major pathologic features is that mucus hypersecretion, airway obstruction, airway inflammation and air flue are high anti-
Ying Xing etc..Asthma is considered as to be caused by the interaction of inherited genetic factors and environmental effect, the infective dose of such as anaphylactogen
With infection time and contact infection etc..At present, inhaled plays a major role in preventing and treating asthma.Although sucking
Glucocorticoid is typically effective, but their high dose or long-time use can cause serious side effect, such as growth
Impaired development, adrenal gland's suppression, fracture, hepatic injury, cancer and apoplexy equivalent risk so that it is on Clinical practice, face one for a long time
Predicament.Therefore, find new, safety, effective medicine to prevent or treat asthma to have become urgent needs.
Summary of the invention
It is an object of the invention to provide the new application of a kind of rosmarinic acid, specifically rosmarinic acid in preparation treatment asthma
Application in medicine.Rosmarinic acid has the advantages such as low toxicity, side effect is little, curative effect is more preferable.
In order to realize object above, the technical solution used in the present invention is as follows:
The present invention provides rosmarinic acid application in preparation treatment asthmatic medicament.
The present invention sets up mouse asthmatic model by ovalbumin (OVA) induction, re-uses dexamethasone and rosmarinic acid
Treatment asthma, confirms the effect of rosmarinic acid treatment asthma by contrast.
The above dexamethasone is the synthetic chemicals effectively treating asthma, is often used as asthma Chinese medicine
The control drug of screening study, but this medicine is asthma chemical drugs, and toxic and side effects is relatively big, and long-term a large amount of uses easily cause exempts from
Epidemic disease suppresses, and causes the side effect such as Abwehrkraft des Koepers decline, growth retardation.
Present invention also offers the pharmaceutically acceptable dosage form of rosmarinic acid, including tablet, powder, granule, injection,
Aerosol and capsule.
Compared with prior art, beneficial effects of the present invention:
The present invention, by substantial amounts of comparative study and pharmacological evaluation, finds that rosmarinic acid has had in preparation treatment asthmatic medicament new
Application, rosmarinic acid is the Chinese medicine monomer extracted from Chinese herbal medicine, has that low toxicity, side effect is little, curative effect is good
Advantage, provides more efficiently medicine for asthmatic patient.
Accompanying drawing explanation
Fig. 1 is the pathological change figure after mouse lung tissue carries out HE dyeing；
Fig. 2 is the pathological change figure after mouse lung tissue carries out AB-PAS dyeing.
In figure: A is normal group, B is model group, and C is rosmarinic acid group, and D is Dexamethasone group.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further described, but is not limited to protection scope of the present invention.
Embodiment 1
1, mouse asthmatic model is set up
Randomly select the female BABL/c mice 48 that body weight is 18-20g, be divided into blank group, model group, rosmarinic acid group
And Dexamethasone group, often group 12；At the 0th day, the 7th day, the 14th day, model group, rosmarinic acid group, Dexamethasone group little
Mus is respectively at lumbar injection OVA(ovalbumin) sensitization liquid, the concentration of OVA is 100 μ g/mL, every injection mice 0.2mL, empty
The PBS of the injected in mice equivalent of white matched group.At the 22-27 days, model group, rosmarinic acid group, Dexamethasone group mice every
It collunarium concentration after etherization is the OVA of 2mg/mL, every mice 50 μ L, Normal group mice collunarium equivalent PBS.
At the 25th, 26,27 days, rosmarinic acid and dexamethasone medicine group every day at mouse peritoneal drug administration by injection, wherein rosmarinic acid:
20mg/kg, dexamethasone: 2mg/kg, excites administration in latter 1 hour.Model group and Normal group inject equivalent at mouse peritoneal
Normal saline, collunarium operation terminated after 24 hours the last time, and sampling carries out follow-up experiment.
, rosmarinic acid is on the impact of classified counting of leucocyte in bronchoalveolar lavage fluid (BALF)
After the operation of above-mentioned mice collunarium the last time terminates 24 hours, ether excessively anaesthetizes execution mice, fixing mice, cuts
Open mice skin of neck, separation and fully expose trachea, above trachea, doing " one " shape otch, inserting self-control and intubate, with injection
Device injects the pre-cooling PBS of 0.5mL, sucking-off after flushing, in triplicate, gathers bronchoalveolar lavage fluid after BALF with 4 DEG C,
The rotating speed of 3000r/min is centrifuged 10 minutes, and supernatant is placed in 80 DEG C of Refrigerator stores for measuring cytokine content in BALF.
Bottom cell precipitation is resuspended in PBS, and cell smear dyes with Switzerland Ji nurse Sa dye liquor, for classified counting of leucocyte.Cell
Differential counting result is as shown in table 1.
Differential blood count (10 in table 1:BALF6Individual/mL)
| Group | Total cellular score | Neutrophilic granulocyte | Eosinophil |
| Blank group | 1.29±0.39 | 0.38±0.12 | 0.016±0.0021 |
| Model group | 5.60±1.10# | 1.67±0.37# | 1.62±0.42# |
| Rosmarinic acid group | 2.87±1.00* | 0.86±0.33** | 0.54±0.18** |
| Dexamethasone group | 2.37±0.85** | 0.71±0.27** | 0.38±0.12** |
Note: # P ＜ 0.01vs. model group, * P ＜ 0.05, * * P ＜ 0.01vs. medicine group.
The above results shows, OVA stimulation causes total cellular score in BALF, neutrophilic granulocyte number and eosinophilic granulocyte's number pole
Significantly increase (p < 0.01).But, rosmarinic acid significantly decreases total cellular score in BALF (p < 0.05), neutrophilic granulocyte number (p
< 0.01) and eosinophilic granulocyte's number (p < 0.01).
, rosmarinic acid is on the impact of IL-4, IL-5 and IL-13 in BALF
After collecting bronchoalveolar lavage fluid, survey according to mice IL-4, IL-5 and IL-13 ELISA detection kit description
Determine the secretion level of IL-4, IL-5 and IL-13 in the mouse allelgic asthma air flue BALF of OVA induction.
Table 2: IL-4, IL-5 and IL-13 concentration (pg/mL) in bronchoalveolar lavage fluid
| Group | IL-4 | IL-5 | IL-13 |
| Blank group | 43.19±7.66 | 11.78±1.02 | 19.73±2.31 |
| Model group | 104.75±4.97# | 33.09±4.83# | 57.50±0.69# |
| Rosmarinic acid group | 63.39±7.42** | 22.21±3.02* | 37.28±4.23** |
| Dexamethasone group | 50.70±6.61** | 15.20±1.42** | 29.56±5.96** |
Note: # P ＜ 0.01vs. model group, * P ＜ 0.05, * * P ＜ 0.01vs. medicine group.
Result shows, compared with normal blank matched group, stimulates through ovalbumin and causes IL-4, IL-5 in model group BALF
Significantly raising (p < 0.01) with IL-13 content, compared with model group, rosmarinic acid and dexamethasone significantly reduce in BALF
Th2 cytokine IL-4(p < 0.01), IL-5(p < 0.05) and IL-13(p < 0.01) concentration.
, rosmarinic acid on asthmatic mouse pathological change affect
The operation of mice collunarium the last time terminates 24 hours, and ether excessively anaesthetizes execution, takes mouse lung tissue respectively, with 4%
Paraformaldehyde solution is fixed, and the dehydration through routine is transparent, waxdip embeds and section exhibition sheet processes, and finally enters lung tissue section
Row HE and AB-PAS dyes, and observes the pathological change of hyper responsiveness of allergic asthmatic mice pulmonary.Result is as depicted in figs. 1 and 2.
As it is shown in figure 1, HE coloration result display blank group alveolar wall structural integrity, alveolar septum thicken without edema and
Inflammatory cell infiltration, OVA induction model group, rosmarinic acid group and Dexamethasone group, mice alveolar septal thickening, bronchus and
Having substantial amounts of inflammatory cell infiltration, and air flue luminal stenosis around blood vessel, generate with rheuminess thing, tracheal smooth muscle is obvious
Thicken, but after rosmarinic acid is treated, around bronchus and blood vessel, lung tissue inflammatory cell number substantially reduces, and tracheal wall is not
Water breakthrough swells, and smooth muscle is also without substantially thickening.
As in figure 2 it is shown, AB-PAS coloration result shows, compared with blank group, the model group of OVA induction, Herba Rosmarini Officinalis
Acid group and Dexamethasone group, epithelial cell number showed increased positive in PAS above mice tracheal wall and with goblet cell
The phenomenon of hypertrophy, mucous secretion significantly increases, and compared with model group, rosmarinic acid group can substantially reduce goblet cell and mucus
Secretion, further relates to rosmarinic acid and has significant therapeutic effect to asthma.
Claims (1)
1. rosmarinic acid application in preparation treatment asthmatic medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610570798.2A CN105997974A (en) | 2016-07-19 | 2016-07-19 | Application of rosmarinic acid to preparing medicines for treating asthma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610570798.2A CN105997974A (en) | 2016-07-19 | 2016-07-19 | Application of rosmarinic acid to preparing medicines for treating asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105997974A true CN105997974A (en) | 2016-10-12 |
Family
ID=57116633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610570798.2A Pending CN105997974A (en) | 2016-07-19 | 2016-07-19 | Application of rosmarinic acid to preparing medicines for treating asthma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105997974A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315863A (en) * | 1998-05-16 | 2001-10-03 | 财团法人牧岩生命工学研究所 | Use of rosmarinic acid and derivatives thereof as immunosuppressant or inhibitor of SHz-mediated process |
| CN1767844A (en) * | 2003-04-08 | 2006-05-03 | 草本制药科学有限责任公司 | Rosmarinic acid composition |
-
2016
- 2016-07-19 CN CN201610570798.2A patent/CN105997974A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315863A (en) * | 1998-05-16 | 2001-10-03 | 财团法人牧岩生命工学研究所 | Use of rosmarinic acid and derivatives thereof as immunosuppressant or inhibitor of SHz-mediated process |
| CN1767844A (en) * | 2003-04-08 | 2006-05-03 | 草本制药科学有限责任公司 | Rosmarinic acid composition |
Non-Patent Citations (1)
| Title |
|---|
| C.SANBONGI等: "Rosmarinic acid in perilla extract inhibits allergic inflammation induced by mite allergen, in a mouse model", 《CLIN EXP ALLERGY 》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100444734C (en) | A compound antivirus sprayer and preparation method thereof | |
| Chen et al. | In vivo study of four preparative extracts of Clematis terniflora DC. for antinociceptive activity and anti-inflammatory activity in rat model of carrageenan-induced chronic non-bacterial prostatitis | |
| Wu et al. | Protective effect of a polyphenolic rich extract from Magnolia officinalis bark on influenza virus-induced pneumonia in mice | |
| CN102106914B (en) | Medicament for treating infectious diseases, preparation method and application thereof | |
| de Almeida et al. | Mandevilla longiflora (Desf.) Pichon improves airway inflammation in a murine model of allergic asthma | |
| Shubhashree et al. | Preventive strategies to combat infections–a review of traditional practices and Ayurveda concepts | |
| CN103784538A (en) | Traditional Chinese medicinal compound drug for effectively preventing and treating swine influenza | |
| CN102335185A (en) | Purpose of icariin in preparation of medicines used for treating bronchial asthma | |
| CN104958419B (en) | The careless capsule for clearing away heat of gold and manufacture craft | |
| CN103720650A (en) | Baicalin injection with anti-influenza virus effect | |
| CN103463182A (en) | Preparation method and application of dracocephalum heterophyllum benth fractionated extracts | |
| CN103239518B (en) | Traditional Chinese medicine composition for treating avian influenza | |
| CN105997974A (en) | Application of rosmarinic acid to preparing medicines for treating asthma | |
| CN102836168B (en) | Application of indole-3-acetonitrile-6-O-beta-D-pyran glucoside in pharmacy | |
| CN105832848A (en) | Traditional Chinese medicine composition for poultry respiratory diseases and preparation method thereof | |
| CN101664441B (en) | Traditional Chinese medicine composition containing isatis leaf and application thereof | |
| CN103768084A (en) | Application of saikosaponin a in preparing medicaments for preventing and treating influenza in human and animals | |
| CN106491957B (en) | It is a kind of for treating the preparation method of the Chinese medicine composition of bronchial asthma | |
| CN100435817C (en) | Medicine for treating rheumatism and rheumatoid diseases and preparing method | |
| CN113975314A (en) | Application of oil of dahurian rhododendron leaf in preparing medicine for preventing or treating respiratory infectious diseases | |
| CN111557961A (en) | A method for treating respiratory diseases by using herba Artemisiae Annuae volatile oil and its administration method | |
| CN101721450B (en) | Application of oriental cocklebur root chloroform extract used for treating peritonitis | |
| CN103436364B (en) | A kind of preparation method of Herba Ajugae volatile oil and application thereof | |
| CN109260192A (en) | Purposes of the qroxylin A in preparation prevention and treatment virus infection of respiratory system drug | |
| CN108030796A (en) | A kind of anaesthetic of resisiting influenza virus and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161012 |
|
| WD01 | Invention patent application deemed withdrawn after publication |